The Impact of Adjuvant Drug Therapy on Overall Survival in Patients with Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.

IF 0.9 4区 医学 Q3 UROLOGY & NEPHROLOGY
Dong Lan, Jianhui Du, Wenqiang Yuan, Qiao Ying, Guohua Huang, Jianhua Lan
{"title":"The Impact of Adjuvant Drug Therapy on Overall Survival in Patients with Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.","authors":"Dong Lan, Jianhui Du, Wenqiang Yuan, Qiao Ying, Guohua Huang, Jianhua Lan","doi":"10.22037/uj.v22i.8540","DOIUrl":null,"url":null,"abstract":"<p><p>Purpose Clear cell renal cell carcinoma (ccRCC), the dominant subtype of renal malignancy, has a rising global incidence and mortality. While surgery is the standard of care for localized cases, adjuvant therapy aims to improve outcomes in high-risk postoperative patients. To quantify the clinical value of adjuvant pharmacotherapy, this systematic review and meta-analysis assesses its effect on overall survival (OS), disease-free survival (DFS), and progression-free survival (PFS) in patients with ccRCC. Materials and Methods A comprehensive search of the Web of Science, Embase, Cochrane Library, and PubMed databases was conducted for articles published up to October 2024. The search used the English keywords \"clear cell renal cell carcinoma,\" \"adjuvant drug therapy,\" and \"randomized controlled trials,\" combined with a free-word search. Randomized controlled trials (RCTs) assessing the effectiveness of at least one adjuvant drug therapy in patients with ccRCC were included. Results The meta-analysis showed that adjuvant drug therapy did not result in a statistically significant improvement for OS or PFS compared to the control group. There was also no statistically significant difference in DFS (P > 0.05). This systematic review provides evidence on the impact of adjuvant targeted therapy on OS, DFS, and PFS for patients with clear cell renal cell carcinoma. Conclusion This study summarizes the effects of adjuvant drug therapy on OS, PFS, and DFS in ccRCC patients. The evidence from this meta-analysis can inform clinical decision-making, support risk-stratification strategies, and encourage the integration of OS-driven endpoints in future trial designs, thereby providing valuable data for the treatment of ccRCC.</p>","PeriodicalId":23416,"journal":{"name":"Urology Journal","volume":" ","pages":""},"PeriodicalIF":0.9000,"publicationDate":"2025-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urology Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.22037/uj.v22i.8540","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose Clear cell renal cell carcinoma (ccRCC), the dominant subtype of renal malignancy, has a rising global incidence and mortality. While surgery is the standard of care for localized cases, adjuvant therapy aims to improve outcomes in high-risk postoperative patients. To quantify the clinical value of adjuvant pharmacotherapy, this systematic review and meta-analysis assesses its effect on overall survival (OS), disease-free survival (DFS), and progression-free survival (PFS) in patients with ccRCC. Materials and Methods A comprehensive search of the Web of Science, Embase, Cochrane Library, and PubMed databases was conducted for articles published up to October 2024. The search used the English keywords "clear cell renal cell carcinoma," "adjuvant drug therapy," and "randomized controlled trials," combined with a free-word search. Randomized controlled trials (RCTs) assessing the effectiveness of at least one adjuvant drug therapy in patients with ccRCC were included. Results The meta-analysis showed that adjuvant drug therapy did not result in a statistically significant improvement for OS or PFS compared to the control group. There was also no statistically significant difference in DFS (P > 0.05). This systematic review provides evidence on the impact of adjuvant targeted therapy on OS, DFS, and PFS for patients with clear cell renal cell carcinoma. Conclusion This study summarizes the effects of adjuvant drug therapy on OS, PFS, and DFS in ccRCC patients. The evidence from this meta-analysis can inform clinical decision-making, support risk-stratification strategies, and encourage the integration of OS-driven endpoints in future trial designs, thereby providing valuable data for the treatment of ccRCC.

辅助药物治疗对透明细胞肾细胞癌患者总生存期的影响:一项系统回顾和荟萃分析。
目的透明细胞肾细胞癌(ccRCC)是肾脏恶性肿瘤的主要亚型,在全球范围内发病率和死亡率都在上升。虽然手术是局部病例的标准治疗,但辅助治疗旨在改善高危术后患者的预后。为了量化辅助药物治疗的临床价值,本系统综述和荟萃分析评估了其对ccRCC患者总生存期(OS)、无病生存期(DFS)和无进展生存期(PFS)的影响。材料与方法对Web of Science、Embase、Cochrane Library和PubMed数据库进行全面检索,检索截止到2024年10月发表的文章。搜索使用英文关键词“透明细胞肾细胞癌”、“辅助药物治疗”和“随机对照试验”,并结合自由词搜索。随机对照试验(RCTs)评估了至少一种辅助药物治疗对ccRCC患者的有效性。结果荟萃分析显示,与对照组相比,辅助药物治疗没有导致OS或PFS的统计学显著改善。两组间DFS差异无统计学意义(P < 0.05)。本系统综述提供了辅助靶向治疗对透明细胞肾细胞癌患者OS、DFS和PFS影响的证据。结论本研究总结了辅助药物治疗对ccRCC患者OS、PFS和DFS的影响。该荟萃分析的证据可以为临床决策提供信息,支持风险分层策略,并鼓励在未来的试验设计中整合操作系统驱动的终点,从而为ccRCC的治疗提供有价值的数据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Urology Journal
Urology Journal UROLOGY & NEPHROLOGY-
CiteScore
2.60
自引率
6.70%
发文量
44
审稿时长
6-12 weeks
期刊介绍: As the official journal of the Urology and Nephrology Research Center (UNRC) and the Iranian Urological Association (IUA), Urology Journal is a comprehensive digest of useful information on modern urology. Emphasis is on practical information that reflects the latest diagnostic and treatment techniques. Our objectives are to provide an exceptional source of current and clinically relevant research in the discipline of urology, to reflect the scientific work and progress of our colleagues, and to present the articles in a logical, timely, and concise format that meets the diverse needs of today’s urologist. Urology Journal publishes manuscripts on urology and kidney transplantation, all of which undergo extensive peer review by recognized authorities in the field prior to their acceptance for publication. Accordingly, original articles, case reports, and letters to editor are encouraged.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信